Age-related uterine changes and its association with poor reproductive outcomes: a systematic review and meta-analysis Authors: Diana Marti-Garcia, Asunta Martinez-Martinez, Francisco Jose Sanz, Almudena Devesa-Peiro, Patricia Sebastian-Leon, Nataly del Aguila, Antonio Pellicer, Patricia Diaz-Gimeno Published: 2024 ABSTRACT BackgroundThe decline in women's fertility becomes clinically relevant between 35–40 years old, when there is insufficient ovarian activity, and it becomes more difficult to achieve pregnancy naturally and through artificial reproductive technologies. A competent endometrium is required for establishing and maintaining a pregnancy to term, however, experts in the field underestimate the contribution of endometrial age and its impact on reproductive outcomes remains unclear.Study designA systematic search of full-text articles available in PubMed was conducted to retrieve relevant studies published until March 2023. Search terms included: endometrium, uterus, age, aging, pregnancy, and oocyte donation. Terms related to reproductive pathologies were excluded. Eligibility criteria included original, rigorous, and accessible peer-reviewed work, published in English on the effect of age on the uterus and endometrium.ResultsFrom 11,354 records identified, 142 studies were included for systematic review, and 59 were eligible for meta-analysis of endometrial thickness (n = 7), pregnancy rate (n = 22), implantation rate (n = 10), live birth rate (n = 10) and pregnancy loss rate (n = 11). Studies for the meta-analysis of reproductive outcomes only included transfers of embryos from ovum donation (ovum donors < 36 years old). Age shrinks the uterus; depletes endometrial blood supply through narrow uterine veins and a progressive loss of uterine spiral arteries; disrupts endometrial architecture and cellular composition; alters hormone production, shortening menstrual cycle length and impeding endometrial progression to the secretory stage; and dysregulates key endometrial functions such as adhesion, proliferation, apoptosis, and receptivity, among others. Women over 35–40 years old had significantly thinner endometrium (MD 0.52 mm). Advanced maternal age is associated with lower odds of achieving implantation (27%) and clinical pregnancy (20%), or higher odds of experiencing pregnancy loss (44%).ConclusionDue to the effect of age on endometrium reported in this review, managing patients with advanced maternal age may require considering the endometrial factor as a potential tissue to treat with anti-aging strategies. This review provides researchers and clinicians with an updated and in-depth summary of this topic, encouraging the development of new tailored anti-aging and preventive strategies for precision medicine in endometrial factor in infertility.Trial registrationPROSPERO 2023 (CRD42023416947).Supplementary InformationThe online version contains supplementary material available at 10.1186/s12958-024-01323-6. Introduction Delayed motherhood due to economic, professional, and lifestyle factors is a major worldwide concern. The mean age of women when their first child is born progressively rose by one year per decade since the 1970s [1]. An age-related decline in women’s fertility begins at 30 years old, becomes clinically relevant between 35–40 years of age, and is exacerbated thereafter [2–4]. To date, there is no universal definition of advanced maternal age (AMA) or international consensus on the threshold age at which women’s fertility declines [5–7]. AMA was associated with reduced ovarian reserves, poor oocyte competence and quality, a higher frequency of chromosome missegregation during meiosis, and elevated blastocyst aneuploidy rates. Together, these mechanisms diminished pregnancy rates while raising miscarriage rates and the prevalence of chromosomal abnormalities in newborns [8, 9]. In this context, current clinical practice mainly focuses on declining ovarian function and oocyte quality in AMA patients, overlooking the effects of age on the uterus and especially on how changes at the endometrial level affect reproductive outcomes [10]. Successful embryo implantation is a key step for human reproduction. A competent endometrium is vital for achieving and sustaining pregnancy. In fact, endometrial factors are estimated to be responsible for 5% to 66% of implantation failures [11–15]. These large discrepancies between studies might be due to different study populations and design. For instance, [14] reported the endometrial contribution was less than 5% in patients with a mean age of 35 and a history of three unsuccessful euploid embryo transfers [14]. Alternatively, using a genome-wide functional approach, our group found that age significantly affected the endometrium when women were older than 35 [2], which suggests that the endometrium can become a therapeutic target to improve pregnancy rates in AMA patients. As endometrial age is not currently considered a clinical risk factor, the existing strategies to improve implantation rates in AMA women rely heavily on embryo selection, oocyte donation, and promoting elective oocyte cryopreservation in younger patients that plan to delay motherhood [16], despite the fact they are not always effective [17]. Molecular evidence has shown human tissues have distinct aging rates, which may differ from the individual’s chronological age. In 2013, Horvath developed a molecular tool, known as Horvath’s epigenetic clock, that determined the molecular age of 51 tissues and cell types by analyzing the methylation patterns of 353 CpG sites. Notably, he found that reproductive tissues, including the endometrium, age earlier than non-reproductive tissues [18]. Aging is a degenerative process characterized by a gradual decrease in cell function and progressive physiological decline [19]. Moreover, tissue aging processes drive the onset of several diseases, such as neurodegenerative diseases, cardiovascular diseases, and cancer [20]. Gaining a better understanding of aging processes, and ultimately, how to delay or reverse them is of public and clinical interest [21]. Current “rejuvenation” strategies in reproductive medicine mainly focus on ovarian pathologies [22–25]. The few advances in endometrial “rejuvenation” strategies were limited to treating pathologies, such as poor endometrial development [26, 27]. It remains to be determined whether there is a deleterious effect of age on the endometrium, and if so, whether there are biomarkers that can help identify target patients with aged endometrial tissue. The endometrial aging process [28, 29] and the effect of age on the uterus and endometrium [30, 31] were recently explored, however, there is still no consensus regarding the associated deleterious effects. To our knowledge, this is the first systematic review to comprehensively assess how age affects endometrial morphology and function in healthy women and the first meta-analysis to evaluate the effects of age on endometrial thickness and reproductive outcomes in an extensive data pool. In contrast to existing reviews [30, 31], we excluded studies performed in animal models or patients with potentially confounding uterine pathologies or low quality aneuploid embryos. Here, we aim to summarize current literature and perform a meta-analysis to gain a better understanding of the effect of age on the uterus, particularly on endometrial morphology and function, and how these changes impact reproductive success in healthy women undergoing artificial reproductive technologies. This review provides valuable insights that can be used to develop new studies or targeted therapies, as well as inform clinical and patient decision-making. Methods Protocol and registration The protocol for this systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration number CRD42023416947). This systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [32]. Search strategy A systematic search of full-text articles available in PubMed was conducted to identify relevant studies published before March 2023. To maximize the number of studies identified, we combined records from searches using MeSH terms and simple terms rather than identifying records manually. Searches included terms related to the endometrium, uterus, age, aging, pregnancy, and oocyte donation but excluded terms related to reproductive pathologies. The specific search queries are presented in Supplementary Table S1. Eligibility criteria and study selection The literature search results were exported to an Excel spreadsheet and duplicates were removed using manual methods. Titles, abstracts, and full-texts were screened independently and in quadruplicate by four authors (D.M.-G., F.S.-L., A.M.-M., and A.D.-P.) using the following eligibility criteria: original, rigorous and accessible peer-reviewed work published in English, on the effects of age on healthy human uterine morphology, endometrial function, and competence (Fig. 1). Studies were excluded if maternal age was not considered an independent study variable or was used as a criteria for applying different clinical protocols, or if age was a risk factor for pregnancy, pregnancy-associated complications (i.e., obstetric, postpartum, fetal, and general postoperative), infections, menopausal/menstrual alterations, or pathology. Studies related to gynecological pathologies and their treatments in AMA patients were also excluded, along with studies including oocytes from donors > 36 years old to minimize as far as possible potential confounding embryo factors. Questions or disagreements were discussed among six authors (D.M.-G., F.S.-L., A.M.-M., A.D.-P., A.P., and P.D.-G.). The final list of included studies was approved by P.D.-G (Fig. 1).Fig. 1Preferred reporting items for systematic reviews and meta-analysis (PRISMA) flowchart Preferred reporting items for systematic reviews and meta-analysis (PRISMA) flowchart Data extraction Extracted data, including the patients’ age, study design, sample size and main findings, uterine evaluation technique (magnetic resonance imaging, transvaginal ultrasound, and histological evaluation), IVF cycle type [natural, hormone replacement therapy (HRT), controlled ovarian stimulation (COS)], IVF cycle characteristics, fertilization method (IVF, ICSI), preimplantation genetic testing for aneuploidies (PGT-A) results, and finally, measures of endometrial thickness and reproductive outcomes following euploid embryo transfer, were compiled into a shared Excel spreadsheet and revised by P.D.-G. Quality assessment Four reviewers independently assessed the quality of the included studies using the study characteristics, statistical analysis performed, the significance of the results (evaluated by the p-value), the presence of data that corroborates the results and conclusions extracted by the authors (i.e., findings or results are supported by data collected in tables, figures or in text), the number of patients included in the statistical comparisons, and the relevance of the results. Moreover, the overall quality of the systematic review is ensured since in each key point of the process (study search and inclusion, data extraction, and quality assessment) results were cross-checked by various authors and supervised by the most experienced one. All articles that did not fulfill the required quality parameters were discarded as irrelevant information during full-text article review. Statistical methods and meta-analysis Meta-analyses were performed in R statistical software version 4.0.5. [33] using the meta R-package version 6.5.0. p-values ≤ 0.05 were considered statistically significant. Studies included for systematic review were selected for meta-analysis if they met the following inclusion criteria: age was evaluated as a discrete variable; sample size was greater than n ≥ 25; there were study groups for both young and AMA patients without an age gap between groups; the mean, standard deviation, and raw data were reported (Supplementary Fig. S1). The quality of the studies included in the meta-analysis was assessed by the Newcastle-Ottawa Scale (NOS) [34]. Categorical variables were analyzed using the Mantel-Haenszel statistical method on binary outcomes and data were expressed as odds ratio (OR). For continuous variables, the inverse variance method was employed, and data were expressed as a pooled mean difference (MD). In both cases, I2 was used to assess the heterogeneity between studies. The 95% confidence interval (CI) was calculated using the random effects model for heterogeneous data (p-value < 0.05), and the common effect model for homogeneous data (p-value > 0.05). Results Search results The results of the systematic literature search are summarized in Fig. 1. A total of 11,354 studies were identified with our search queries. Following removal of duplicates (n=195), titles and abstracts were screened for eligibility based on the exclusion criteria presented in (Fig. 1) and 529 (4.7%) full-text studies were retrieved for detailed assessment. We classified studies by the effect(s) of age on the uterus, endometrium and reproductive outcomes. Finally, 142 studies were included for systematic review, including 12 (8.4%) related to uterine morphology (Table 1), 17 (11.9%) assessing endometrial and uterine vasculature (Table 2), 10 (7.0%) evaluating endometrial histology (Table 3), 31 (21.8%) measuring endometrial thickness (Table 4), 18 (12.6%) evaluating menstrual or hormonal changes (Fig. 2A and B), 14 (9.8%) investigating endometrial biomolecules (Fig. 3), and 51 (35.9%) exploring the effects on reproductive outcomes (Supplementary Table S2). Table 1Effect of age on uterine morphologyVariabletypeAge (years) / stageNumber of patients (n)TechniqueEffect of ageSummary of reported resultsReferenceULUWUAPUVUTUWeUSDiscrete15–24; 25–34; 35–45200MRIYes---- --[35]Continuous ≤ 50210TVSNo-NS-----[36]Discrete45–49; 50–54; 55–59; 60–64; 65–69; 70–74815TVS or TASYes--- (> 45) NS--[37]ContinuousNA807TVSNo------NS[38]Continuous15–45231USGYes------ [39]Discrete < 25; 25–30; 30–35; ≥ 355,726TVSYes --- [40]Continuous0–401,418TASYes--- ---[41]DiscreteMP stages146TVSYes- (PostMP) (PostMP) (PostMP) ---[42]DiscretePreMPvsPostMP263TVSYesNo (PostMP) ------------NS[43]Discrete15–24; 25–34; 35–44; 45–54; 55–64; 65–74; ≥ 75308PMEYes----- (15–54) -[44]Continuous0–915,466USGYes (0–40) (40–91) (25–38) (38–55) (25–40) (40–55) ----[45]Continuous17–8272MRIYes--- (17–40) (45–82) ---[46]The upwards (red) and downwards (blue) arrows were used to respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parenthesesMP menopause, MRI magnetic resonance imaging, NA not available, NS not significant, PME post-mortem examination, TAS transabdominal ultrasonography, TVS transvaginal ultrasonography, UAP uterine antero-posterior length, UL uterine length, US uterine size, USG ultrasonography, UT uterine thickness, UV uterine volume, UW uterine width, UWe uterine weightTable 2Effect of age on endometrial and uterine vasculatureVariable typeAge (years) / stageNumber of patients (n)TechniqueEffect of ageSummary of reported resultsReferenceEFIEVIEVFIECaUSVPIUVDRIIADiscreteMP stages(20–60)486TVSYes------ (PostMP) (41–50) --[47]Continuous < 6058CDFINo-----NS---[48]Discrete30–34; 35–39; 40–44152CDFINo-----NS-NS-[49]DiscretePreMP vs. PostMP74HBAYes-------- (PostMP) [50]Discrete < 31; 31–33; 34–36; > 36793D-PDUYes(33) (33) (33) ------[51]Discrete < 40 vs. > 4021TVCDUNo-----NS-NS-[52]Discrete ≤ 30 vs. > 30110TVCDUNo-----NS-NS-[53]Discrete ≤ 34; 35–39; ≥ 40143DUSNo-----NS---[10]DiscreteReproductive age vs PostMPNANAYes--- (Post MP)----[54]Continuous52–9610ICP-OESYes--- (≥ 70) (≥ 90) -----[55]Discrete ≤ 30; 31–35; 36–40; ≥ 416383D-PDUNoNSNSNS------[56]Continuous27–8628ICP-OESYes--- (≥ 60) -----[57]Discrete ≤ 35 vs. > 35884CDFIYes----- (≥ 35) ---[58]Discrete < 31 vs. ≥ 31273-PDAYes (≥ 31) --------[59]Continuous21–4094DUSNo-----NS---[60]Discrete < 35 vs. ≥ 35439USGYes (≥ 35) (≥ 35) (≥ 35) ---- (≥ 35) -[61]Discrete < 25; 25–29; 30–34; ≥ 351993D-PDUYesNSNSNS- (< 25) (≥ 35) ----[62]The upwards (red) and downwards (blue) arrows respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parentheses3D-PDA 3D power doppler angiography, 3D-PDU 3D power doppler ultrasound, CDFI colour doppler flow imaging, DUS Doppler ultrasound, EC elements content, EFI endometrial flow index, EVFI endometrial vascular flow index, EVI endometrial vascular index, HBA histological biometric analysis, IA intimal area, ICP-OES Inductively Coupled Plasma Optical Emission spectroscopy, MP menopause, NA not available, NS not significant, PI pulsatility index, RI resistance index, TVCDU transvaginal color Doppler ultrasound, TVS transvaginal ultrasound, USG ultrasonography, USV uterine spiral vasculature, UVD uterine vein diameteraEvaluated minerals included calcium, phosphorus, magnesium, and sodiumTable 3Effect of age on endometrial histologyVariable typeAge (years) / stageNumber of patients (n)TechniqueEffect of ageSummary of reported resultsReferenceEndometrial Histological PatternsOthersDiscretePostMP12HBANoNS-[63]Discrete20–30 vs. 40–5060HBANoNS according to Noyes’ criteria-[64]Discrete20–30 vs. 30- 4029DTINo-NS for fractional anisotropyNS for apparent diffusion coefficient[65]Continuous45–65NASEMYes- Microvillus secretory cells (> 52) Ciliated cell numberAlterations in non-ciliated cells[66]Continuous25–6956SWENo-NS for endometrial elasticity[67]NANA477TVSNoNS according to Noyes’ criteria-[68]Continuous22–4350HSCNoPoor Glandular epithelium (> 37) [69]Discrete25–39; 40–49; 50–60122HBANoNS according to Noyes’ criteria Glandular maturity (> 55) [70]Discrete < 41 vs. 41–45191USGYesPoor (41–45)-[71]Discrete23–35 vs. 36–4158HBAYesNormal (< 35)-[72]Parameters with statistical differences were specified along with the corresponding age groups in brackets. The downward blue arrows indicate a significant decreaseDTI 3T diffusion tensor imaging, HBA histologic biometric analysis, HSC hysteroscopy, MP menopause, NA not available, NS not significant, SEM scanning electron microscopy, SWE shear wave elastography, TVS transvaginal ultrasonography, US ultrasonographyTable 4Effect of age on endometrial thicknessVariable typeAge (years) / stageSample size (n)Type of cycleWhen endometrial thickness was measuredTechniqueEffect of agingSummary of reported resultsReferenceDiscrete17–25; 26–35; 36–40; > 402,334 pCOShCG dayTVSYES [73]Discrete15–24; 25–34; 35–45200 pNANAMRIYES [35]Discrete18–35 vs. 45–5526 pNaturalEvery 1–3 days before ovulationTVSYES [74]Discrete ≤ 30; 31–35; 36–40; 41–45; 46–53189 pHRTNATVSNONS[75]Discrete < 70 vs. ≥ 7036 pHRTNATVSNONS[76]Discrete < 40 vs. ≥ 4078 cHRThCG dayNAYES [77]Discrete < 40 vs. ≥ 4078 cHRTDonor’s hCG dayTVSYES [78]Discrete21–35; 36–40; 41–49; 50–61141 cHRTDays 8, 11, 15 and 21 of the cycleTVSNONS[79]Continuous < 423,157 cCOShCG dayNAYES [80]Discrete ≤ 34; 35–39; ≥ 40143 cHRT2 h prior to embryo transferNANONS[10]ContinuousNA1,016 pCOShCG dayTVSNONS[81]ContinuousNA274 pHRT > 12 days after E4 was administratedTVSNONS[82]DiscreteReproductive age vs Post MPNANANANAYES PostMP [54]DiscreteMP stages146 pNaturalDay 2 to 8 of the cycleTVSYES PostMP [42]Continuous20–41120 pNANATVSNONS[83]Continuous52–8326 pNANACTGYES [84]Continuous ≤ 409,255 cNatural or HRThCG dayNAYES [85]DiscretePreMP vs. PostMP263 pNaturalDays 4 and 8 of the cycleTVSYES (PostMP) [43]ContinuousNA477 pCOShCG day + 1TVSYES [68]Discrete25–39; 40–49; 50–60122 pHRTDay 21 of the cycleTVSNONS[70]ContinuousNA1,111 pNatural or HRTDay 8 to 10 of the cycleTVSYES [86]ContinuousNA10,165 pHRTEmbryo transfer dayTVSYES a [87]Discrete < 35 vs. > 351,169 pCOSNANAYES [88]Continuous24–40103 pCOShCG dayTVSYES [89]Discrete ≤ 35; 36–40; 41–422,343 pNAhCG dayTVSYES [90]Discrete < 35 vs. > 352,562 pNatural or HRTDaily from day 10TVSYES [91]Discrete22–34 vs 41–4661 pNatural7 days after the temperature shiftTVSNONS[92]Discrete < 35 vs. ≥ 35439 pNaturalDay 8 of the cycle and 2 days prior to ovulationTVSNONS[61]ContinuousPost MP8,594 pNANATVSYES [93]ContinuousNA783 pCOShCG dayTVSYES [94]Continuous < 406,181 pNatural + hCG or HRThCG day (natural) or prior P4 initiation (HRT)TVSNONS[95]The upwards (red) and downwards (blue) arrows respectively showcase significant age-related increases or decreases in endometrial thickness. If the significant changes were associated with a particular age group, the group was specified in parenthesesc cycles, COS controlled ovarian stimulation, CTG computed tomography, HRT hormone replacement therapy, MRI magnetic resonance imaging, MP menopause, NA not available, NS not significant, p patients, TVS transvaginal ultrasoundaIn this study by Shaodi et al., increased endometrial thickness was found in the youngest and oldest groupsFig. 2Main findings of studies evaluating the effect of age on reproductive hormone levels and menstrual cycle disturbances. Comparison of hormone levels and endometrial progression in young women and those of advanced maternal age. With age, the levels of serum anti-mullerian hormone (AMH), androgen, estrogen, LH, and FSH decline. These changes collectively lead to menstrual cycle disturbances, marked by a shorter proliferative phase, higher prevalence of uterine atrophy and out-of-phase endometria. AMH, antimullerian hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; Created with BioRender.comFig. 3Main findings of studies evaluating the effect of age on molecular mechanisms and functions of the endometrium. Summary of the main findings of studies evaluating age-related functions disruptions of the uterus or endometrium, including those reported by single and high throughput experimental approaches. MKI67 is related to regulation of chromosome segregation and mitotic nuclear division, CNNA1 is related to control of meiosis, and MCM2 is related to initiation of genome replication. CCNA1, cyclin-A1; CXCL12, CXC motif chemokine ligand 12; CXCL14, CXC motif chemokine ligand 14; HOXA10, homeobox A10 DNA-binding transcription factor; IL17RB, interleukin-17 receptor B; IL8, interleukin-8; LIF, leukemia inhibitory factor cytokine; MCM2, minichromosome maintenance complex component 2; MKI67, marker of proliferation Ki-67; MUC1, mucin 1; NS, not significant; PGR, progesterone receptor. Created with BioRender.com Table 1Effect of age on uterine morphologyVariabletypeAge (years) / stageNumber of patients (n)TechniqueEffect of ageSummary of reported resultsReferenceULUWUAPUVUTUWeUSDiscrete15–24; 25–34; 35–45200MRIYes---- --[35]Continuous ≤ 50210TVSNo-NS-----[36]Discrete45–49; 50–54; 55–59; 60–64; 65–69; 70–74815TVS or TASYes--- (> 45) NS--[37]ContinuousNA807TVSNo------NS[38]Continuous15–45231USGYes------ [39]Discrete < 25; 25–30; 30–35; ≥ 355,726TVSYes --- [40]Continuous0–401,418TASYes--- ---[41]DiscreteMP stages146TVSYes- (PostMP) (PostMP) (PostMP) ---[42]DiscretePreMPvsPostMP263TVSYesNo (PostMP) ------------NS[43]Discrete15–24; 25–34; 35–44; 45–54; 55–64; 65–74; ≥ 75308PMEYes----- (15–54) -[44]Continuous0–915,466USGYes (0–40) (40–91) (25–38) (38–55) (25–40) (40–55) ----[45]Continuous17–8272MRIYes--- (17–40) (45–82) ---[46]The upwards (red) and downwards (blue) arrows were used to respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parenthesesMP menopause, MRI magnetic resonance imaging, NA not available, NS not significant, PME post-mortem examination, TAS transabdominal ultrasonography, TVS transvaginal ultrasonography, UAP uterine antero-posterior length, UL uterine length, US uterine size, USG ultrasonography, UT uterine thickness, UV uterine volume, UW uterine width, UWe uterine weight Effect of age on uterine morphology PreMP vs PostMP Yes No (PostMP) - - - - - - - - - - - - NS (0–40) (40–91) (25–38) (38–55) (25–40) (40–55) (17–40) (45–82) The upwards (red) and downwards (blue) arrows were used to respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parentheses MP menopause, MRI magnetic resonance imaging, NA not available, NS not significant, PME post-mortem examination, TAS transabdominal ultrasonography, TVS transvaginal ultrasonography, UAP uterine antero-posterior length, UL uterine length, US uterine size, USG ultrasonography, UT uterine thickness, UV uterine volume, UW uterine width, UWe uterine weight Table 2Effect of age on endometrial and uterine vasculatureVariable typeAge (years) / stageNumber of patients (n)TechniqueEffect of ageSummary of reported resultsReferenceEFIEVIEVFIECaUSVPIUVDRIIADiscreteMP stages(20–60)486TVSYes------ (PostMP) (41–50) --[47]Continuous < 6058CDFINo-----NS---[48]Discrete30–34; 35–39; 40–44152CDFINo-----NS-NS-[49]DiscretePreMP vs. PostMP74HBAYes-------- (PostMP) [50]Discrete < 31; 31–33; 34–36; > 36793D-PDUYes(33) (33) (33) ------[51]Discrete < 40 vs. > 4021TVCDUNo-----NS-NS-[52]Discrete ≤ 30 vs. > 30110TVCDUNo-----NS-NS-[53]Discrete ≤ 34; 35–39; ≥ 40143DUSNo-----NS---[10]DiscreteReproductive age vs PostMPNANAYes--- (Post MP)----[54]Continuous52–9610ICP-OESYes--- (≥ 70) (≥ 90) -----[55]Discrete ≤ 30; 31–35; 36–40; ≥ 416383D-PDUNoNSNSNS------[56]Continuous27–8628ICP-OESYes--- (≥ 60) -----[57]Discrete ≤ 35 vs. > 35884CDFIYes----- (≥ 35) ---[58]Discrete < 31 vs. ≥ 31273-PDAYes (≥ 31) --------[59]Continuous21–4094DUSNo-----NS---[60]Discrete < 35 vs. ≥ 35439USGYes (≥ 35) (≥ 35) (≥ 35) ---- (≥ 35) -[61]Discrete < 25; 25–29; 30–34; ≥ 351993D-PDUYesNSNSNS- (< 25) (≥ 35) ----[62]The upwards (red) and downwards (blue) arrows respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parentheses3D-PDA 3D power doppler angiography, 3D-PDU 3D power doppler ultrasound, CDFI colour doppler flow imaging, DUS Doppler ultrasound, EC elements content, EFI endometrial flow index, EVFI endometrial vascular flow index, EVI endometrial vascular index, HBA histological biometric analysis, IA intimal area, ICP-OES Inductively Coupled Plasma Optical Emission spectroscopy, MP menopause, NA not available, NS not significant, PI pulsatility index, RI resistance index, TVCDU transvaginal color Doppler ultrasound, TVS transvaginal ultrasound, USG ultrasonography, USV uterine spiral vasculature, UVD uterine vein diameteraEvaluated minerals included calcium, phosphorus, magnesium, and sodium Effect of age on endometrial and uterine vasculature MP stages (20–60) (Post MP) (≥ 70) (≥ 90) (< 25) (≥ 35) The upwards (red) and downwards (blue) arrows respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parentheses 3D-PDA 3D power doppler angiography, 3D-PDU 3D power doppler ultrasound, CDFI colour doppler flow imaging, DUS Doppler ultrasound, EC elements content, EFI endometrial flow index, EVFI endometrial vascular flow index, EVI endometrial vascular index, HBA histological biometric analysis, IA intimal area, ICP-OES Inductively Coupled Plasma Optical Emission spectroscopy, MP menopause, NA not available, NS not significant, PI pulsatility index, RI resistance index, TVCDU transvaginal color Doppler ultrasound, TVS transvaginal ultrasound, USG ultrasonography, USV uterine spiral vasculature, UVD uterine vein diameter aEvaluated minerals included calcium, phosphorus, magnesium, and sodium Table 3Effect of age on endometrial histologyVariable typeAge (years) / stageNumber of patients (n)TechniqueEffect of ageSummary of reported resultsReferenceEndometrial Histological PatternsOthersDiscretePostMP12HBANoNS-[63]Discrete20–30 vs. 40–5060HBANoNS according to Noyes’ criteria-[64]Discrete20–30 vs. 30- 4029DTINo-NS for fractional anisotropyNS for apparent diffusion coefficient[65]Continuous45–65NASEMYes- Microvillus secretory cells (> 52) Ciliated cell numberAlterations in non-ciliated cells[66]Continuous25–6956SWENo-NS for endometrial elasticity[67]NANA477TVSNoNS according to Noyes’ criteria-[68]Continuous22–4350HSCNoPoor Glandular epithelium (> 37) [69]Discrete25–39; 40–49; 50–60122HBANoNS according to Noyes’ criteria Glandular maturity (> 55) [70]Discrete < 41 vs. 41–45191USGYesPoor (41–45)-[71]Discrete23–35 vs. 36–4158HBAYesNormal (< 35)-[72]Parameters with statistical differences were specified along with the corresponding age groups in brackets. The downward blue arrows indicate a significant decreaseDTI 3T diffusion tensor imaging, HBA histologic biometric analysis, HSC hysteroscopy, MP menopause, NA not available, NS not significant, SEM scanning electron microscopy, SWE shear wave elastography, TVS transvaginal ultrasonography, US ultrasonography Effect of age on endometrial histology NS for fractional anisotropy NS for apparent diffusion coefficient Microvillus secretory cells (> 52) Ciliated cell number Alterations in non-ciliated cells Parameters with statistical differences were specified along with the corresponding age groups in brackets. The downward blue arrows indicate a significant decrease DTI 3T diffusion tensor imaging, HBA histologic biometric analysis, HSC hysteroscopy, MP menopause, NA not available, NS not significant, SEM scanning electron microscopy, SWE shear wave elastography, TVS transvaginal ultrasonography, US ultrasonography Table 4Effect of age on endometrial thicknessVariable typeAge (years) / stageSample size (n)Type of cycleWhen endometrial thickness was measuredTechniqueEffect of agingSummary of reported resultsReferenceDiscrete17–25; 26–35; 36–40; > 402,334 pCOShCG dayTVSYES [73]Discrete15–24; 25–34; 35–45200 pNANAMRIYES [35]Discrete18–35 vs. 45–5526 pNaturalEvery 1–3 days before ovulationTVSYES [74]Discrete ≤ 30; 31–35; 36–40; 41–45; 46–53189 pHRTNATVSNONS[75]Discrete < 70 vs. ≥ 7036 pHRTNATVSNONS[76]Discrete < 40 vs. ≥ 4078 cHRThCG dayNAYES [77]Discrete < 40 vs. ≥ 4078 cHRTDonor’s hCG dayTVSYES [78]Discrete21–35; 36–40; 41–49; 50–61141 cHRTDays 8, 11, 15 and 21 of the cycleTVSNONS[79]Continuous < 423,157 cCOShCG dayNAYES [80]Discrete ≤ 34; 35–39; ≥ 40143 cHRT2 h prior to embryo transferNANONS[10]ContinuousNA1,016 pCOShCG dayTVSNONS[81]ContinuousNA274 pHRT > 12 days after E4 was administratedTVSNONS[82]DiscreteReproductive age vs Post MPNANANANAYES PostMP [54]DiscreteMP stages146 pNaturalDay 2 to 8 of the cycleTVSYES PostMP [42]Continuous20–41120 pNANATVSNONS[83]Continuous52–8326 pNANACTGYES [84]Continuous ≤ 409,255 cNatural or HRThCG dayNAYES [85]DiscretePreMP vs. PostMP263 pNaturalDays 4 and 8 of the cycleTVSYES (PostMP) [43]ContinuousNA477 pCOShCG day + 1TVSYES [68]Discrete25–39; 40–49; 50–60122 pHRTDay 21 of the cycleTVSNONS[70]ContinuousNA1,111 pNatural or HRTDay 8 to 10 of the cycleTVSYES [86]ContinuousNA10,165 pHRTEmbryo transfer dayTVSYES a [87]Discrete < 35 vs. > 351,169 pCOSNANAYES [88]Continuous24–40103 pCOShCG dayTVSYES [89]Discrete ≤ 35; 36–40; 41–422,343 pNAhCG dayTVSYES [90]Discrete < 35 vs. > 352,562 pNatural or HRTDaily from day 10TVSYES [91]Discrete22–34 vs 41–4661 pNatural7 days after the temperature shiftTVSNONS[92]Discrete < 35 vs. ≥ 35439 pNaturalDay 8 of the cycle and 2 days prior to ovulationTVSNONS[61]ContinuousPost MP8,594 pNANATVSYES [93]ContinuousNA783 pCOShCG dayTVSYES [94]Continuous < 406,181 pNatural + hCG or HRThCG day (natural) or prior P4 initiation (HRT)TVSNONS[95]The upwards (red) and downwards (blue) arrows respectively showcase significant age-related increases or decreases in endometrial thickness. If the significant changes were associated with a particular age group, the group was specified in parenthesesc cycles, COS controlled ovarian stimulation, CTG computed tomography, HRT hormone replacement therapy, MRI magnetic resonance imaging, MP menopause, NA not available, NS not significant, p patients, TVS transvaginal ultrasoundaIn this study by Shaodi et al., increased endometrial thickness was found in the youngest and oldest groups Effect of age on endometrial thickness The upwards (red) and downwards (blue) arrows respectively showcase significant age-related increases or decreases in endometrial thickness. If the significant changes were associated with a particular age group, the group was specified in parentheses c cycles, COS controlled ovarian stimulation, CTG computed tomography, HRT hormone replacement therapy, MRI magnetic resonance imaging, MP menopause, NA not available, NS not significant, p patients, TVS transvaginal ultrasound aIn this study by Shaodi et al., increased endometrial thickness was found in the youngest and oldest groups Main findings of studies evaluating the effect of age on reproductive hormone levels and menstrual cycle disturbances. Comparison of hormone levels and endometrial progression in young women and those of advanced maternal age. With age, the levels of serum anti-mullerian hormone (AMH), androgen, estrogen, LH, and FSH decline. These changes collectively lead to menstrual cycle disturbances, marked by a shorter proliferative phase, higher prevalence of uterine atrophy and out-of-phase endometria. AMH, antimullerian hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; Created with BioRender.com Main findings of studies evaluating the effect of age on molecular mechanisms and functions of the endometrium. Summary of the main findings of studies evaluating age-related functions disruptions of the uterus or endometrium, including those reported by single and high throughput experimental approaches. MKI67 is related to regulation of chromosome segregation and mitotic nuclear division, CNNA1 is related to control of meiosis, and MCM2 is related to initiation of genome replication. CCNA1, cyclin-A1; CXCL12, CXC motif chemokine ligand 12; CXCL14, CXC motif chemokine ligand 14; HOXA10, homeobox A10 DNA-binding transcription factor; IL17RB, interleukin-17 receptor B; IL8, interleukin-8; LIF, leukemia inhibitory factor cytokine; MCM2, minichromosome maintenance complex component 2; MKI67, marker of proliferation Ki-67; MUC1, mucin 1; NS, not significant; PGR, progesterone receptor. Created with BioRender.com Effect of age on uterine morphology Among the studies investigating how uterine morphology changes with age (Table 1), seven studies corroborated there is a gradual increase in uterine weight, volume and/or size, which is more pronounced during adolescence when the uterus transitions from a tubular to an inverted pear shape, but there was no consensus on the threshold age when the uterus begins to shrink [35, 39–41, 44–46]. These results contradict earlier evidence of there being no change in uterine size before menopause [43]. Of those studies reporting these rising trends, five found a further progressive reduction, although there was no consensus on the threshold age. One study reported a decrease in uterine length and volume when women reach 35–40 years [45], two reported uterine size lessened postmenopause [42, 43], and two showed uterine volume declined after 45 years of age [37, 46]. Recent evidence shows age leads to an incremental thickening of the uterine wall, particularly in the fundus [35], and a rounded shape of the uterus [40, 45]. However, when Verguts et al. took into account parity, they only found this change of shape in women who had conceived [45]. In contrast, two articles did not find a relationship between age and uterine morphologic parameters [36, 38], although one observed that there was a rising trend of uterine body lengths in older women [38]. Finally, two groups reported that the enlarged uterine size in premenopausal women was related to parity rather than age [36, 43]. However, these findings were contradicted by a more recent study reporting differences in the uterine morphology of nulligravida women [40]. Effect of age on endometrial and uterine vasculature Ten of the seventeen studies evaluating the effect of age on uterine vasculature reported statistically significant changes with age, including decreased uterine blood flow, supply and poor morphology (Table 2). Notably, two studies found significant mineral accumulation (i.e., calcium, sodium and phosphorus) in the uterine arteries of older women [55, 57], while others reported altered structure and morphology of uterine vasculature with age [47, 50, 51, 54, 58, 59, 61, 62]. Specifically, age was associated with a higher intimal area and a lower medial area of uterine arteries [50]. Uterine veins dilated until 41–50 years of age, then constricted [47]. Similarly, uterine spiral arterioles volume dwindled from age 35 [54, 62]. There were contradictory results on whether functional uterine vasculature is affected by age. Three functional studies revealed reduced vascular and flow indexes with age [51, 59, 61] while two studies did not find any differences in these parameters [56, 62]. On the other hand, six studies evidenced age was not related to the resistance and/or pulsatility indexes [10, 48, 49, 52, 53, 60] while two studies found an increase of pulsatility or resistance index [58, 61]. Effect of age on endometrial histology In general, studies evaluating changes in healthy endometrial histology with age revealed poorer endometrial histological patterns and echogenicity coupled with cellular alterations (Table 3). Three studies evaluating endometrial biopsies using Noyes’ criteria [96] found no significant differences in histological patterns: one study included women undergoing HRT and biopsies collected on day 21 of the menstrual cycle; the second included women with regular menstrual cycles and biopsies collected 7–9 days after the luteinizing hormone (LH) peak; and the third included women who underwent COS and had biopsies collected the morning after hCG administration [64, 70, 96]. However, these studies all reported a decrease of glandular maturity in women over 55 years old. Similarly, there were no significant histological differences in the endometrial tissue of menopausal women assessed using Novak and Richardson’s criteria [63]. Women under 35 years old presented better endometrial histology, however the criteria for this examination was not reported [72]. Notably, the two studies that found alterations in endometrial histology with age established their own criteria [69, 71] and observed less glandular epithelium in women over 37 years old [69]. In these studies, endometrial biopsies were collected on the day of the ovulation trigger or 7–9 days after natural ovulation. Finally, the postmenopausal reduction in ciliated cell numbers and alteration in non-ciliated cells indicated endometrial cellular compartments are affected by age [66]. Other histological parameters employed to evaluate the effect of age included the fractional anisotropy value and the apparent diffusion coefficient, which define the rate of local water diffusion, during different phases of the menstrual cycle. While these parameters did not significantly differ with age, the fractional anisotropy values tended to be higher in older women [65]. Age did not affect endometrial elasticity, as measured using shear wave elastography [67]. Effect of age on endometrial thickness Among the 31 studies that compared endometrial thickness in young and AMA women (Table 4), 17 (54.8%) reported the endometrial lining gets thinner with age [42, 43, 54, 68, 73, 77, 78, 80, 84–86, 88–91, 93, 94], 11 (35.4%) found no statistical differences [10, 61, 70, 75, 76, 79, 81–83, 92, 95], one argued that thicker endometrial linings corresponded with the youngest and oldest age groups [87], and two reported the endometrium thickens with age [35, 74]. Effect of age on menstrual cycle characteristics Eight studies (80%) corroborated that age negatively affects ovarian hormone levels (Table 5). There was evidence of significantly reduced levels of plasma oestradiol and oestradiol-17β or serum androstenedione (a precursor of active androgens and oestrogens) in menopausal women compared to menstruating women [63, 97], and diminished estrogen and progesterone levels [98]. However, a recent study reported no differences in preovulatory serum progesterone or progesterone/oestradiol ratios in women under 45 years old [99], which corroborated earlier evidence that there were no differences in endometrial oestrogen or progesterone receptor expression between menstruating and peri-menopausal women [100]. Notably, there are lower levels of oestrogen receptors in the endometrial glands of women over 51 years old [101]. Further, older women presented elevated follicle stimulating hormone (FSH) and luteinizing hormone (LH) serum levels [64, 92, 98, 102] and lower basal androgen levels in serum [103]. Table 5Effect of age on sex hormones levelsVariable typeAge or age ranges (years)/ stagesNumber of total patientsEffect of ageSummary of reported resultsReferenceEndometriumOvariesPlasmaE2 or P4 receptorsE2P4E1/E2P4Androgen levelsFSHLHDiscretePreMP vs. PostMP40Yes--- (Post MP)----[63]Discrete20–30 vs. 40–5032Yes------ (> 40) (> 40) [64]DiscreteMenstruatingvs. PostMP75Yes----- (Post MP)--[97]DiscreteReproductive age89NoNS-------[100]Discrete21–25, 26–31, 32–36, 37–4553Yes------ [102]Continuous18–5121Yes- (≥ 46) (≥ 46) --- (≥ 46) -[98]Continuous51–8333Yes -------[101]Continuous ≤ 45203No---NSNS---[99]Continuous20–455,278Yes----- --[103]Discrete22–34 vs. 41–4661Yes------ (41–46) (41–46) [92]The upwards (red) and downwards (blue) arrows were used to respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parenthesesE2 estrogen, FSH follicle-stimulating hormone, LH luteinizing hormone, NS not significant, P4 progesterone, PreMP pre-menopause, PostMP post-menopause Table 5Effect of age on sex hormones levelsVariable typeAge or age ranges (years)/ stagesNumber of total patientsEffect of ageSummary of reported resultsReferenceEndometriumOvariesPlasmaE2 or P4 receptorsE2P4E1/E2P4Androgen levelsFSHLHDiscretePreMP vs. PostMP40Yes--- (Post MP)----[63]Discrete20–30 vs. 40–5032Yes------ (> 40) (> 40) [64]DiscreteMenstruatingvs. PostMP75Yes----- (Post MP)--[97]DiscreteReproductive age89NoNS-------[100]Discrete21–25, 26–31, 32–36, 37–4553Yes------ [102]Continuous18–5121Yes- (≥ 46) (≥ 46) --- (≥ 46) -[98]Continuous51–8333Yes -------[101]Continuous ≤ 45203No---NSNS---[99]Continuous20–455,278Yes----- --[103]Discrete22–34 vs. 41–4661Yes------ (41–46) (41–46) [92]The upwards (red) and downwards (blue) arrows were used to respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parenthesesE2 estrogen, FSH follicle-stimulating hormone, LH luteinizing hormone, NS not significant, P4 progesterone, PreMP pre-menopause, PostMP post-menopause Effect of age on sex hormones levels (Post MP) Menstruating vs. PostMP (Post MP) The upwards (red) and downwards (blue) arrows were used to respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parentheses E2 estrogen, FSH follicle-stimulating hormone, LH luteinizing hormone, NS not significant, P4 progesterone, PreMP pre-menopause, PostMP post-menopause Eight studies reported that menstrual cycle progression is altered with age (Table 6). Earlier studies showed age led to uterine atrophy, irregular menstrual cycles [104, 105], and a progressive decline in menstrual cycle duration [98]. However, a later work found no differences in the menstrual cycle duration of older women [92, 102]. There is contradictory evidence on whether age alters the length of the follicular and luteal phases of the menstrual cycle. While most studies demonstrated that the follicular phase shortens with age [92, 98, 106], one study reported the opposite [102]. On the other hand, two studies demonstrated that age was not related to altered luteal phase length [92, 102] contradicting previous evidence by [98] describing that age lengthens the luteal phase. Finally, age was associated with an inadequate transformation to the secretory phase, impaired development of functional endometrium [72, 107], and a higher prevalence of out-of-phase endometria [104]. A summary of the age-related changes in reproductive hormone levels and menstrual cycle disturbances is depicted in Fig. 2. Table 6Effect of age on menstrual cycleVariable typeAge range (years)Number of patientsEffect of ageStatistically significant changes with ageReferenceMCRCDFPLLPEPDNANA2,054Yes-- --[106]Discrete21–25 vs. 37–4553Yes-NS (37–45) NS-[102]Continuous18–5121Yes- -[98]Discrete < 35 vs. > 3533Yes---- [107]Discrete < 40 vs. > 4036Yes (> 40) --- [104]Discrete23–35 vs. 36–4158Yes---- [72]NANANAYes ----[105]Discrete22–34 vs. 41–4661Yes-NS (41–46) NS-[92]The upwards (red) and downwards (blue) arrows were used to respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parenthesesCD cycle duration, EPD endometrial phase displacement, FPL follicular phase length, LP luteal phase, MCR menstrual cycle regularity, NA not available, NS not significant Table 6Effect of age on menstrual cycleVariable typeAge range (years)Number of patientsEffect of ageStatistically significant changes with ageReferenceMCRCDFPLLPEPDNANA2,054Yes-- --[106]Discrete21–25 vs. 37–4553Yes-NS (37–45) NS-[102]Continuous18–5121Yes- -[98]Discrete < 35 vs. > 3533Yes---- [107]Discrete < 40 vs. > 4036Yes (> 40) --- [104]Discrete23–35 vs. 36–4158Yes---- [72]NANANAYes ----[105]Discrete22–34 vs. 41–4661Yes-NS (41–46) NS-[92]The upwards (red) and downwards (blue) arrows were used to respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parenthesesCD cycle duration, EPD endometrial phase displacement, FPL follicular phase length, LP luteal phase, MCR menstrual cycle regularity, NA not available, NS not significant Effect of age on menstrual cycle The upwards (red) and downwards (blue) arrows were used to respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parentheses CD cycle duration, EPD endometrial phase displacement, FPL follicular phase length, LP luteal phase, MCR menstrual cycle regularity, NA not available, NS not significant Effect of age on biomolecule levels Single experiment approaches Among the ten studies using single experimental molecular analyses like polymerase chain reaction (PCR) or western blot, eight found that age significantly altered molecular functions of the uterus and endometrium (Fig. 3 and Table 7). Older women had reduced levels of MK167 (Marker Of Proliferation Ki-67), MCM2 (Minichromosome Maintenance Complex Component 2), and CCNA1 (Ciclin A1), suggesting alterations in cell cycle and proliferation [108]. E-cadherin downregulation [109] suggested adhesion is also disturbed with age, however, expression of other adhesion markers, such as MUC1 (Mucin 1), LIF (Leukaemia inhibitory factor), integrin-β3, and glycoconjugate sugar residue content and distribution (related to peri-implantation feto-maternal molecular recognition) remained stable [109–111]. Notably, older women presented lower levels of HOXA10 (Homeobox A10), a well-known marker of endometrial receptivity [112]; elevated endometrial apoptosis and senescence [113]; and higher proportion of p16-positive senescent cells in the uterine epithelium and endometrial glands [114]. Age-related metabolic disturbances include reduced glucose uptake coupled with lower cytochrome oxidase and succinate dehydrogenase activity in the endometrium [115]. Whereas age-related immune system perturbations include altered levels of chemokines, particularly CXCL12 (C-X-C Motif Chemokine Ligand 12), CXCL14 (C-X-C Motif Chemokine Ligand 14), and IL17RB (Interleukin 17 Receptor B) [116]. Finally, the downregulation of the aryl hydrocarbon receptor with age suggested that this transcription factor might have a relevant role in women of reproductive age [117]. Table 7Effect of age on molecular mechanisms and functions of the endometriumFunctionComparison typeAge (years)Sample sizeTissueEffect of ageStatistically significant changes with ageReferenceCell cycle and proliferationContinuous25-5514Cultured endometriumYES HOXA10 [112]Groups18 – 38 vs 45–5444Endometrium and serumYES MKI67, MCM2, CCNA1, PGR and response to steroids (45–54)[108]AdhesionContinuous21-2851EndometriumYES E-cadherin [109]Groups < 30 vs > 4030EndometriumNONS glycoconjugate sugar residue content and distribution[110]Continuous < 4059EndometriumNONS MUC1, LIF and integrin-beta3[111]ApoptosisContinuous28-3834Endometrium and serumYES Apoptotic index [113]Immune systemContinuous24-4820EndometriumYES CXCL12, CXCL14 and IL17rb NS IL8 levels[116]MetabolismGroups ≤ 35; ≥ 36-45; ≥ 461500EndometriumYES Glucose uptake ≥ 46 Cytochrome oxidase and succinate dehydrogenase activity[115]SenescenceContinuous22-48311EndometriumYES Proportion of p16-positive senescent cells [114]OthersGroups25-31; 32-38; 39-4586EndometriumYES Endometrial reactivity for arylhydrocarbon receptor [117]The upwards (red) and downwards (blue) arrows were used to respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parenthesesCCNA1 cyclin-A1, CXCL12 CXC motif chemokine ligand 12, CXCL14 CXC motif chemokine ligand 14, IL17RB interleukin-17 receptor B, IL8 interleukin-8, LIF leukemia inhibitory factor cytokine, MCM2 minichromosome maintenance complex component 2, MKI67 marker of proliferation Ki-67, MUC1 mucin 1, NS not significant, PGR progesterone receptor Table 7Effect of age on molecular mechanisms and functions of the endometriumFunctionComparison typeAge (years)Sample sizeTissueEffect of ageStatistically significant changes with ageReferenceCell cycle and proliferationContinuous25-5514Cultured endometriumYES HOXA10 [112]Groups18 – 38 vs 45–5444Endometrium and serumYES MKI67, MCM2, CCNA1, PGR and response to steroids (45–54)[108]AdhesionContinuous21-2851EndometriumYES E-cadherin [109]Groups < 30 vs > 4030EndometriumNONS glycoconjugate sugar residue content and distribution[110]Continuous < 4059EndometriumNONS MUC1, LIF and integrin-beta3[111]ApoptosisContinuous28-3834Endometrium and serumYES Apoptotic index [113]Immune systemContinuous24-4820EndometriumYES CXCL12, CXCL14 and IL17rb NS IL8 levels[116]MetabolismGroups ≤ 35; ≥ 36-45; ≥ 461500EndometriumYES Glucose uptake ≥ 46 Cytochrome oxidase and succinate dehydrogenase activity[115]SenescenceContinuous22-48311EndometriumYES Proportion of p16-positive senescent cells [114]OthersGroups25-31; 32-38; 39-4586EndometriumYES Endometrial reactivity for arylhydrocarbon receptor [117]The upwards (red) and downwards (blue) arrows were used to respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parenthesesCCNA1 cyclin-A1, CXCL12 CXC motif chemokine ligand 12, CXCL14 CXC motif chemokine ligand 14, IL17RB interleukin-17 receptor B, IL8 interleukin-8, LIF leukemia inhibitory factor cytokine, MCM2 minichromosome maintenance complex component 2, MKI67 marker of proliferation Ki-67, MUC1 mucin 1, NS not significant, PGR progesterone receptor Effect of age on molecular mechanisms and functions of the endometrium MKI67, MCM2, CCNA1, PGR and response to steroids (45–54) CXCL12, CXCL14 and IL17rb NS IL8 levels Glucose uptake ≥ 46 Cytochrome oxidase and succinate dehydrogenase activity The upwards (red) and downwards (blue) arrows were used to respectively showcase significant age-related increases or decreases in the evaluated parameters. If the significant changes were associated with a particular age group, the group was specified in parentheses CCNA1 cyclin-A1, CXCL12 CXC motif chemokine ligand 12, CXCL14 CXC motif chemokine ligand 14, IL17RB interleukin-17 receptor B, IL8 interleukin-8, LIF leukemia inhibitory factor cytokine, MCM2 minichromosome maintenance complex component 2, MKI67 marker of proliferation Ki-67, MUC1 mucin 1, NS not significant, PGR progesterone receptor High-throughput experimental approaches Recent omics findings confirmed that age negatively impacts uterine physiology [118] and alters uterine epigenetics [29] and microbiota [119] (Fig. 3). Transcriptomic assays of menstrual blood-derived stem cells from women of different age groups exposed a downregulation of genes related to the cell cycle, proliferation, adhesion, metabolism and growth factor receptors, along with an upregulation of genes involved in apoptosis and immune responses with age [118]. Further, analysis of multiple endometrial transcriptomic data sets revealed the endometria of older women were more susceptible to SARS-CoV-2 infection due to overexpression of target proteins, including ACE2 (Angiotensin Converting Enzyme 2, the main target for SARS-CoV-2) [120]. On the other hand, age alters endometrial DNA methylation profiles [18]. Horvath’s epigenetic clock showed a good correlation between the chronological age of women and the endometrial molecular age when the phase of menstrual cycle was taken into consideration [29], although this correlation was less accurate in young women [29]. Finally, the uterine microbiota becomes less diversified with age, resembling that of the vaginal microbiome [119]. There is an increased Firmicutes to Proteobacteria ratio in women over 40 and these changes become more evident in women over 50 [119]. Effect of age on reproductive outcomes We identified 51 studies that investigated the effects of age on reproductive outcomes following good quality embryo transfer with autologous euploid embryos or embryos generated from oocytes derived from donors < 36 years old (Supplementary Table S2). Of these, 23 (45.1%) reported maternal age negatively impacted reproductive outcomes and 28 (54.9%) found no statistical differences. Meta-analysis Endometrial thickness Seven studies (22.5%) met the quality criteria for meta-analysis (Supplementary Fig. S1A, Supplementary Table S3A) and reported the mean endometrial thickness, measured during distinct phases of the menstrual cycle, in a total of 5,126 women. The quality assessment of the included studies is reflected in Supplementary Table S4A. The forest plot with the MDs in endometrial thickness is presented in Fig. 4. Our meta-analysis confirmed that AMA (defined here as 35–40 years old) was associated with a reduced endometrial thickness, regardless of the menstrual cycle phase (MD [95% CI] = −0.52 mm [−0.72, −0.32], I2 = 76%, p-value < 0.0001).Fig. 4Forest plot of mean difference from the meta-analysis of endometrial thickness in women with advanced maternal age. MD: mean difference; CI: confidence interval Forest plot of mean difference from the meta-analysis of endometrial thickness in women with advanced maternal age. MD: mean difference; CI: confidence interval Reproductive outcomes Pregnancy rate The forest plot with the calculated ORs for PR is presented in Fig. 5A. Analyzing data for 52,843 embryo transfers in donor oocyte cycles (oocyte donors < 36 years old) (34,425 in the AMA patients and 18,418 in the young patients (Supplementary Table S3B)) across 22 eligible studies (Supplementary Fig. S1B), the odds of achieving clinical pregnancy were 20% lower for AMA patients (OR 0.80; 95% CI: 0.69, 0.93; I2 = 55%, p-value = 0.0039). Age considered for AMA in pregnancy rate studies was 39–42, being 40 years old the most common cutoff age. The quality assessment of the included studies is reflected in Supplementary Table S4B. Live birth rate The forest plot with the calculated ORs for LBR is presented in Fig. 5B and the quality assessment of the included studies is reflected in Supplementary Table S4C. Analyzing data for 26,111 clinical pregnancies (17,552 in the AMA patients and 8,559 in the young patients (Supplementary Table S3C)) across 10 eligible studies (Supplementary Fig. S1C) there was no significant decrease in the odds of achieving a live birth for AMA patients (OR 0.96, 95% CI: 0.91, 1.01, I2 = 44%, p-value = 0.0953). Age considered for AMA in live birth rate studies was 40 years old. Implantation rate The forest plot with the calculated ORs for IR is presented in Fig. 5C. The quality assessment of the included studies is reflected in Supplementary Table S4D. Analyzing data for 69,384 embryo transfers from donor oocytes cycles (oocyte donors < 36 years old) (44,754 in the AMA patients and 24,630 in the young patients (Supplementary Table S3D)) across 10 eligible studies (Supplementary Fig. S1D) the odds of successful implantation diminished by 27% for AMA patients (OR 0.73, 95% CI: 0.57, 0.93, I2 = 75%, p-value = 0.0108). Age considered for AMA in implantation rate studies was 39–41, being 40 years old the most common cutoff age. Pregnancy loss rate The forest plot with the calculated ORs for PLR is presented in Fig. 5D. Analyzing data for 20,798 clinical pregnancies (13,421 in the AMA patients and 7,361 in the young patients (Supplementary Table S3E)) across 11 eligible studies (Supplementary Fig. S1E), the odds of miscarriage were 44% higher for AMA patients (OR 1.44, 95% CI: 1.04, 1.99, I2 = 60%, p-value = 0.0278). The quality assessment of the included studies is reflected in Supplementary Table S4E. Age considered for AMA in pregnancy loss rate studies was 39–42, being 40 years old the most common cutoff age.Fig. 5Forest plots of odds ratios from the meta-analyses of reproductive outcomes in women with advanced maternal age. Forest plots for the OR of achieving (A) clinical pregnancy, (B) live birth, (C) implantation, or experiencing (D) pregnancy loss following euploid embryo transfer. OR, odds ratio; CI, confidence interval Forest plots of odds ratios from the meta-analyses of reproductive outcomes in women with advanced maternal age. Forest plots for the OR of achieving (A) clinical pregnancy, (B) live birth, (C) implantation, or experiencing (D) pregnancy loss following euploid embryo transfer. OR, odds ratio; CI, confidence interval Discussion Main findings Overall, the results presented in this systematic review point to an influence of age in the uterus and endometrium on various levels. Contradictory evidence in qualifying literature may have been due to different study designs, methodologies, and cohorts. Our meta-analysis showed that AMA patients had significantly reduced endometrial thickness, lower odds of a successful implantation and achieving clinical pregnancy, or higher odds of pregnancy loss, but no significant differences in the odds of achieving a live birth, compared to younger patients. Further, given all the inclusion and exclusion criteria used in these meta-analyses, we consider that only high quality studies were included; hence reinforcing the relevance of the obtained results. The uterus is a hollow organ that acquires its inverted pear shape at the onset of puberty [121] and is implicated in gestation [122]. Overall, studies included in this review showed that the human uterus enlarges until approximately menopause, then begins shrinking [35, 37, 39–46]. A recently published study confirmed a significant relationship between age and uterine morphology [123]. This observation suggests that sex hormones are implicated in these morphological changes, since the rise and drop of their levels respectively correlate with the first and the last menstrual cycle. Supporting the hypothesis that the onset of menses promotes uterine enlargement, there is a direct relationship between serum estradiol levels and uterine length in young women between 8 and 16 years old [124]. Further, girls with Turner syndrome are treated with estrogen replacement therapy to promote uterine development and growth [125]. However, after puberty, it remains unclear whether age affects gross uterine morphology. Parity is considered to have a larger influence on uterine size than age [36, 43, 123], however, most of the studies evaluating the effect of age on uterine morphology, reviewed herein, did not consider parity. Thus, further studies would be required to confirm if uterine size is affected by age, parity, or a combination of both factors. Uterine size is important for reproductive outcomes since a minimum size is required to achieve a successful pregnancy [126]. Leading to menopause, the diminished activity of the few ovarian follicles leads to an inadequate production of inhibin B and estradiol, raising serum FSH through a loss of negative feedback to the hypothalamus [92, 98, 127]. The augmented FSH levels accelerate follicular growth, shortening the follicular phase by three to four days while maintaining the normal timeframe for ovulation and the luteal phase [92, 106, 127]. As a consequence of the perimenopausal hormonal shift and marked decline in estrogen levels, the endometrium undergoes changes that may displace the window of implantation [128] and/or lead to endometrial atrophy (i.e., thinning of the uterine lining) [129]. These age-related disturbances in endometrial development might explain the reported alterations in tissue architecture and cellular composition [69, 71]. Interestingly, studies that did not observe histological differences in the endometrium of older women employed Noyes’ criteria [96], the most commonly used method for endometrial dating. This suggests that Noyes’ criteria may not detect age-related alterations, adding to the established limitations of these guidelines (i.e., inter- and intra-subject variability, interobserver variability, and inability to determine fertility status) [130, 131]. Regarding the changes in endometrial cell composition with age, our search identified an early study which detected there were fewer ciliated cells and alterations in non-ciliated cells in older women, using integrated transmission and scanning electron microscopy [66]. However, our recent functional analysis showed that functions related to cilia motility and ciliogenesis are upregulated in AMA patients [2]. Similar in silico findings were experimentally validated by Loid and colleagues [132], confirming ample ciliated cells in the endometrial tissue of AMA patients using immunohistochemical analysis. Ciliated cells are important for reproductive biology [133] and their abundance fluctuates throughout the menstrual cycle. The larger proportions of ciliated cells during the late proliferative phase help the embryo(s) roll over the uterine lumen while smaller proportions at the window of implantation help weaken the endometrial barrier to facilitate trophoblast invasion [133, 134]. Thus, excessive ciliated cells and cilia motility in AMA patients could hinder embryo implantation. Uterine atrophy is characterized by a thin endometrial lining and loss of endometrial glands [135]. Apart from a good-quality embryo, a minimum endometrial thickness is required to support embryo implantation [136]. However, there is a long-standing debate on whether endometrial thickness is associated with reproductive outcomes in AMA patients. A recent single-center, retrospective, observational study demonstrated that ongoing pregnancy rates increase by 12% per millimeter of endometrial thickness for women over 35 years undergoing frozen-thawed embryo transfers [91]. Our meta-analysis confirmed the mean endometrial thickness was reduced by 0.52 mm in women 35 to 40 years old compared to women < 35 years old, suggesting that aging and its associated physiological and endocrine changes impede adequate endometrial development. Our results align with those of a previous meta-regression [137] that grouped women based on endometrial thickness (≤ 7 mm vs. > 7 mm) and found the mean age of patients with thin endometrium (≤ 7 mm) was significantly higher than that of patients with adequate endometrial thickness (> 7 mm) [137]. Given that thin endometria are characterized by poor epithelial growth, decreased vascular endothelial growth factor (VEGF) expression, and poor vascular development and blood flow [138], the age-related decline in endometrial thickness and hormonal fluctuations may also be related to changes in endometrial vasculature. This review highlights AMA patients have vascular disturbances that decrease uterine blood supply, which may impede endometrial receptivity, and ultimately, affect reproductive outcomes following euploid embryo transfer. In the early stages of embryo implantation, active angiogenesis, confirmed by the upregulation of various angiogenesis-related factors, supports embryonic development and the establishment of pregnancy [139]. While a relationship exists between endometrial blood flow and reproductive outcomes [140, 141], previous studies used limited sample sizes and there was no consensus regarding the vascular parameters (e.g., pulsatility or resistance indexes) that may be affected by age. Our review begins to address these gaps by highlighting that AMA patients have histologic features of elevated mineral depositions in the uterine blood vessels [55, 57] that may drive uterine artery atherosclerosis. Elevated vascular calcification was recently related to a higher risk of developing atherosclerosis [142], a disease well-known to affect postmenopausal women [50]. Notably, atherosclerosis was associated with vascular stiffness and limited vasodilation [143]. As uterine vascular remodeling is essential for cyclical endometrial development, preparing for embryo implantation, placentation, and maintenance of pregnancy [144], the implications of this condition during childbearing years merit further investigation. Studies evaluating the effect of age on the endometrium using functional genomic analyses have identified key genes and processes required for endometrial competence. Specifically, embryo implantation was hindered by dysregulated adhesion [145], immune modulation [146], glucose metabolism [147, 148], proliferation [149], apoptosis [150], and endometrial receptivity [151]. Further, our group identified 5,778 dysregulated endometrial genes in women over 35 years old, including genes essential for endometrial receptivity acquisition [Progestagen associated endometrial protein (PAEP) and matrix metallopeptidase 26 (MMP26)], cell cycle arrest [Fibroblast growth factor 2 (FGF2)], maintenance of telomeric length [TERF1 interacting nuclear factor 2 (TINF2)], and genomic stability [Sirtuin 1 (SIRT1)] [2]. Age-related declines in stromal cell proliferation and repression of crucial decidualization factors, signal transducer and activator of transcription 3 (STAT3) and bone morphogenetic protein-2 (BMP2), were also reported [152]. Notably, it was also reported that epigenetic endometrial molecular age was increased compared to chronological age, and that this increase was more pronounced in younger women [29]. This increase in the endometrial molecular age might be due to estrogen and/or progesterone activity, two hormones that have a key role in the endometrium [153]. In fact, it has been observed that mutations in estrogen and progesterone receptors, such as in several breast cancer types, lead to an increase of molecular age [18]. On the other hand, disrupted DNA methylation, may lead to premature endometrial aging, which hinders endometrial receptivity and embryo implantation [154]. In fact, DNA methylation of 448 sites exerted a detrimental effect on endometrial receptivity, leading to recurrent pregnancy failure [155]. Additionally, DNA methylation analysis suggests that senescent endometrial stromal cells partially contribute to decreased endometrial plasticity, which may lead to recurrent pregnancy loss [156]. This phenomenon is consistent with findings from studies presented in this review that indicate that endometrial histological patterns deteriorate with age. Moreover, parallel to studies on the gut microbiome [157], the endometrial microbiome evolves to have a lower biodiversity with age. A dysbiosis caused by the pathological Proteobacterium overgrowing the beneficial Lactobacillus negatively affected endometrial receptivity and reproductive outcomes [128, 158]. Taken together, epigenetic alterations, mitochondrial dysfunction, deregulated nutrient sensing, cellular senescence, and microbial dysbiosis–which are all established hallmarks of human aging–reinforce the concept of endometrial aging [19, 159, 160]. Understanding how age affects uterine morphology, histology, and cell compartments helps elucidate the impact on endometrial competence, or ability to achieve, maintain, and successfully carry a pregnancy to term. Our meta-analysis included only studies with good-quality embryos (derived from oocytes donated from women < 36 years old). This approach reduced potential confounding embryonic factors to unmask endometrial factors. Overall, we found that, compared to younger women, AMA patients had significantly lower odds of establishing and maintaining pregnancy, and tended to have lower odds of a live birth, although the latter was not statistically significant. Given the positive correlation between AMA and gestational and/or fetal complications [161], it is possible that a statistical difference was not detected due to an insufficient sample size. Overall, results obtained in our meta-analysis suggest that the detrimental effect of age on reproductive outcomes influenced only by the endometrial factor might begin around 40 years. A recent meta-analysis evaluating the endometrial receptivity of young versus AMA patients in donor oocyte cycles found a non-significant decline in the clinical pregnancy rates and an increase in PLR in AMA women, but a similar IR and LBR between AMA and young women [162]. The discrepancies between the findings reported by Zhao and colleagues [162] and those herein may be due to differences in the pooled sample sizes or the existence of uterine pathologies. However, supporting our results, this review also stablish 40 years as the age cutoff at which a worsening in the reproductive outcomes induced by the endometrial factor begins. Two other reviews published in 2023 evaluated the effect of age on reproductive outcomes. One concluded that there was no clear relationship between AMA and poor reproductive outcomes [30]. However, this group included studies where infertile patients undergoing IVF donated their oocytes to other infertile patients of advanced age, which may have confounded the study results. The second, by Wu et al., also suggested there were more adverse pregnancy outcomes and pregnancy complications in older patients, but these authors mainly reviewed studies performed in animal models, which may not accurately extrapolate to humans [31]. Strengths and limitations To our knowledge, this is the first systematic review that comprehensively evaluates how age affects the morphology and function of the endometrium, incorporating meta-analyses to discern whether AMA affects endometrial thickness and reproductive outcomes following euploid embryo transfer. Prior to this work, the scarcity of rigorous studies accounting for embryonic effects and uterine pathologies when evaluating the endometrial competence of AMA women likely contributed to the contradicting evidence. Additionally, studies that found no statistically significant differences might have been limited by different study characteristics. Not detecting age-related differences does not guarantee they do not exist, especially when other studies identified them. Despite strict inclusion criteria for meta-analysis, there was significant heterogeneity between studies, due to different study designs (prospective and retrospective), endometrium preparation protocols (replaced, natural, and stimulated), embryo states (fresh and frozen) and sample sizes. However, we controlled for the AMA cut-off age in our meta-analyses (35-40 years for endometrial thickness and 39-42 for the four reproductive outcomes). Although we excluded studies of AMA patients with uterine disorders because they might potentially mask the effects of age on endometrium, we acknowledge that the risks of these diseases increase with age. Further, these diseases have subclinical manifestations and/or are often underdiagnosed, and thus, may be present in the “healthy” patients that were included. Despite these limitations this meta-analysis provides valuable insights into the effect of age on endometrium, due to the large data pool, novel and relevant results. Implications for future research Studies on endometrial aging were scarce or included confounding factors that gave rise to contradicting evidence. Well-designed studies are required to elucidate if post-pubertal uterine enlargement is due to age or parity, and if there are other molecular mechanisms that disrupt endometrial histology and hinder the acquisition of endometrial competence in older women. Implications for clinical practice As increasingly more women delay motherhood, clinicians are faced with the challenges that accompany an aging reproductive system, including impaired ovarian and uterine function. Understanding the mechanisms of uterine aging will help older women make informed decisions knowing their likelihood of success and help clinicians guide evidence-based reproductive medicine to improve the outcomes of assisted reproductive technologies. Identifying patients with premature uterine aging, then attempting to delay or reverse the aging processes will shift the landscape for personalized medicine and help manage AMA patients seeking assisted reproductive technologies. Conclusion In conclusion, this systematic review and meta-analysis highlights the existence of age-related mechanisms affecting the uterus and the endometrium, reinforcing the importance of adequate endometrial function for successful establishment and maintenance of pregnancy in AMA patients. The effect of age on the uterus and endometrium was characterized by uterine shrinkage, diminished blood supply, impaired endometrial architecture, altered cell components, thin endometrial linings, and molecular perturbations that are all directly implicated in preimplantation endometrial development and the embryo-endometrium crosstalk during and after implantation. Future studies can use these insights to develop anti-aging therapies or preventive measures for endometrial “rejuvenation” that ultimately aim to improve the reproductive outcomes of AMA patients. Supplementary Information Supplementary Material 1.Supplementary Material 2. Supplementary Material 1. Supplementary Material 2.